Inhibition of basal and metoclopramide-induced prolactin release by cabergoline, an extremely long-acting dopaminergic drug.
The aim of this study was to evaluate the effectiveness of the ergoline derivative cabergoline in inhibiting the serum PRL response to metoclopramide (MCP; 5 mg, iv) and the duration of this effect. Seven normal men received cabergoline (600 micrograms, orally) on day 0 and underwent a MCP test on days -1, 1, 4, 8, 15, and 28. Fasting serum PRL levels were significantly depressed from days 1-14; the nadir value occurred on day 4. MCP-induced PRL release was significantly inhibited up to day 28, with a nadir on day 4. Two months later, four of the men received placebo on day 0, and tests with MCP were performed on days -1, 8, and 28; basal serum PRL levels and PRL responses to MCP were superimposable on days -1, 8, and 28. These data indicate that cabergoline is an effective long-acting inhibitor of PRL release in normal men, suitable for use in the management of hyperprolactinemic patients.
Pontiroli
A E
AE
Istituto Scientifico San Raffaele, Cattedra di Clinica Medica, Università di Milano, Italy.
Cammelli
L
L
Baroldi
P
P
Pozza
G
G
D000328:Adult; D000077465:Cabergoline; D004298:Dopamine / Q000502:physiology*; D004873:Ergolines / Q000494:pharmacology*; D006801:Humans; D008297:Male; D008787:Metoclopramide / Q000494:pharmacology*; D011388:Prolactin / Q000037:antagonists & inhibitors* / Q000097:blood; D013268:Stimulation, Chemical; D013997:Time Factors
D004873:Ergolines; D011388:Prolactin; D008787:Metoclopramide; D000077465:Cabergoline; D004298:Dopamine